Why testosterone levels drop and when to consider treatment
Don't count on daily aspirin to prevent colon cancer
Night owls' habits linked to worse heart health
After ablation, exercise may lower atrial fibrillation recurrence
What can cause an enlarged heart?
Women's unique risks for heart disease
Chronic kidney disease: A hidden threat to your heart
Navigating your online patient portal: Best practices
Treating hair loss in men: What works?
Virtual cardiac rehab: Heal your heart from home
Adam S. Cheifetz, MD
Contributor
Dr. Adam Cheifetz is director of the center for inflammatory bowel disease and medical director of infusion services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School. He is a well-recognized leader in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. He is involved in multiple research projects relating to IBD, and has published over 200 articles and chapters on the subject.
His research currently focuses on therapeutic drug monitoring and optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care.
Why testosterone levels drop and when to consider treatment
Don't count on daily aspirin to prevent colon cancer
Night owls' habits linked to worse heart health
After ablation, exercise may lower atrial fibrillation recurrence
What can cause an enlarged heart?
Women's unique risks for heart disease
Chronic kidney disease: A hidden threat to your heart
Navigating your online patient portal: Best practices
Treating hair loss in men: What works?
Virtual cardiac rehab: Heal your heart from home
